Pharmafile Logo

ProBioGen: Change in Management

May 2, 2024 – Biotechnology, Drug Discovery –

30 April 2024 – Berlin, Germany – Biotech Newswire – ProBioGen AGa premier Contract Development and Manufacturing Organisation (CDMO) and technology provider with extensive expertise in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals, and MiGenTra GmbH, a subsidiary of ProBioGen AG and Minapharm Pharmaceuticals SAE (Egypt), today announce a change of management:

Alfred Merz, PhD, has been appointed as chief operating officer effective May 1st, 2024. He follows Dr Lutz Hilbrich as interim CEO, who is leaving at his own request by a mutual termination agreement. Dr Alfred Merz joins from BAYER Pharmaceuticals where he held the position of senior vice president & head of Product Supply Medical Devices. Alfred looks back on 30 years international experience in manufacturing, operational excellence and strategy development with leading pharmaceuticals and biotech- companies including Bayer and Novartis in Europe and the USA. He is a certified pharmacist and holds an MBA from St. Gallen University, Switzerland. Dr Lutz Hilbrich joined the company as CEO of ProBioGen AG in June 2020 and is also CEO of its subsidiary MiGenTra GmbH.

Dr Wafik Bardissi, chairman of the Supervisory Board of ProBioGen AG and CEO and Chairman of the parent Company Minapharm thanks Dr. Lutz Hilbrich for his contribution over the past years and welcomes Dr. Alfred Merz to lead a sustainable growth strategy at ProBioGen.

Dr Bardissi commented: “Alfred‘s strategic vision and proven international track record ln Europe and the USA in driving operational excellence, manufacturing and strategy development make him an ideal candidate to prop up ProBioGen’s next phase of innovation and expansion.“

ProBioGen
info@probiogen.de
Herbert-Bayer-Straße 8 13086 Berlin